Wellbutrin Tapering Guide
bupropion
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial treatment.
Overview
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) approved for major depressive disorder, seasonal affective disorder, and smoking cessation (as Zyban). It is unique among antidepressants for its activating profile and lack of sexual side effects or weight gain.
75mg, 100mg, 150mg, 300mg
Immediate-release tablets: 75mg, 100mg; Sustained-release tablets (SR): 100mg, 150mg, 200mg; Extended-release tablets (XL): 150mg, 300mg
Category C (risk cannot be ruled out)
Mechanism of Action
Inhibits reuptake of norepinephrine and dopamine (NDRI). Does not significantly affect serotonin reuptake. The active metabolites hydroxybupropion, threohydrobupropion, and erythrohydrobupropion also contribute to pharmacological activity.
Taper Notes
Generally easier to taper than SSRIs/SNRIs. IR tablets can be split for gradual reduction.
Hyperbolic Tapering Guidance
Reduce gradually. IR formulation provides most flexibility for dose adjustments.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Tapering Protocol
Evidence-based phased reduction schedule. Always taper under medical supervision.
| Phase | Duration | Notes |
|---|---|---|
| Initial reductions | 2-4 weeks | Use available XL strengths. Most tolerate initial steps well. |
| Formulation switch | 2-4 weeks | Your prescriber may switch to SR or IR formulation for more flexible adjustments. |
| Final reductions | 4-6 weeks | IR tablets offer the most flexibility. Bupropion withdrawal is generally milder than SSRI/SNRI discontinuation. |
Withdrawal Timeline
1-3 days after dose reduction
3-7 days
1-2 weeks for most symptoms
Fatigue and motivational deficits may linger 2-4 weeks. No serotonin-related symptoms (no brain zaps). Wellbutrin has one of the mildest withdrawal profiles among antidepressants.
Community Tips
Practical insights shared by members tapering Wellbutrin. Not medical advice — always consult your prescriber.
- 1Wellbutrin withdrawal is fundamentally different from SSRIs — no brain zaps, no serotonin discontinuation syndrome. The main issues are fatigue, low motivation, and mild mood dips.
- 2Ask your prescriber about IR tablets for the final phase — they offer more flexibility than XL or SR formulations.
- 3Do not crush or split XL or SR tablets — they are designed for extended release. Cutting them can increase seizure risk.
- 4Some members report increased appetite and mild weight gain when stopping Wellbutrin, which normalizes over several weeks.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- MAOIs — contraindicated (hypertensive crisis)
- Potent CYP2D6 inhibitor; increases levels of TCAs, SSRIs (paroxetine, fluoxetine levels affected less), metoprolol, flecainide, and other CYP2D6 substrates
- CYP2B6 inhibitors (ticlopidine, clopidogrel) increase bupropion levels
Food Interactions
- Food does not significantly affect SR/XL absorption
- Avoid alcohol (lowers seizure threshold)
Contraindications
- Seizure disorder
- Current or prior bulimia or anorexia nervosa (increased seizure risk)
- MAOIs within 14 days
Toxicity
Dose-dependent seizure risk (contraindicated above 450mg/day). Hypertension. Lower toxicity in overdose than TCAs but seizures and cardiac conduction delays possible.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Tmax ~2 hours (IR), ~3 hours (SR), ~5 hours (XL). Extensive first-pass metabolism; bioavailability ~5–20%. Food does not significantly affect absorption of SR/XL formulations.
~20 L/kg (estimated)
Extensively metabolized hepatically via CYP2B6 (primary) to the active metabolite hydroxybupropion. Non-CYP pathways produce threohydrobupropion and erythrohydrobupropion.
Renal (~87%, with <1% as unchanged bupropion) and fecal (~10%).
~84%
~200 L/hr (apparent oral clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Wellbutrin (bupropion) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Davies J, Read J 2019 — Discontinuation symptoms after treatment with serotonergic and noradrenergic antidepressants — a systematic review (Addictive Behaviors)
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper framework) (The Lancet Psychiatry)
- Patel K, Allen S, Haque MN, et al. 2016 — Bupropion: a review of its use in the management of major depressive disorder (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms for antidepressants
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on antidepressant discontinuation
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — Wellbutrin (bupropion) tapering forum — Community archive of Wellbutrin discontinuation experiences
- Mad in America — Wellbutrin archive — Journalism and personal narratives on bupropion
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.